Ovid director granted 65,000 stock options

DUNCAN BARBARA GAYLE reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

DUNCAN BARBARA GAYLE reported acquisition or exercise transactions in this Form 4 filing.

Ovid Therapeutics director Barbara Gayle Duncan received a grant of employee stock options covering 65,000 shares on February 26, 2026. The options have a stated price of $0.0000 per share and will vest in full on February 26, 2027, subject to her continuous service through that vesting date.

Insider Trade Summary

Grant/Award: 65,000 shares

Grant/Award 1 txn

Insider DUNCAN BARBARA GAYLE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	65,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 65,000 contracts (Direct)

Footnotes (1)

1. F1. The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OVID director Barbara Gayle Duncan report?

Barbara Gayle Duncan reported receiving an employee stock option grant for 65,000 shares. The award is a derivative security, reflecting a grant or other acquisition, and is tied to her role as a director of Ovid Therapeutics Inc. under the company’s equity compensation arrangements.

When do Barbara Gayle Duncan’s new OVID stock options vest?

The options will vest in full on February 26, 2027. Vesting is conditioned on her continuous service with Ovid Therapeutics through that date, meaning she must remain in her role without interruption for the entire vesting period.

What is the size of the OVID stock option grant to Barbara Gayle Duncan?

The grant covers 65,000 employee stock options. After this award, the Form 4 shows 65,000 derivative securities owned following the transaction, indicating this is a new grant rather than a partial addition to an existing option position.

What transaction code is used for Barbara Gayle Duncan’s OVID option grant?

The transaction is reported under code “A,” which represents a grant, award, or other acquisition. This confirms the options were granted to her, rather than purchased on the open market or acquired through an exercise of previously granted derivatives.

Is Barbara Gayle Duncan’s ownership in this OVID Form 4 direct or indirect?

The Form 4 classifies her ownership of these options as direct. The ownership code is shown as “D,” and no footnote indicates that the options are held through a trust, partnership, or other related entity on her behalf.

Does the OVID Form 4 show any stock sales by Barbara Gayle Duncan?

The Form 4 reports only an acquisition of derivative securities and no sales. It shows one transaction coded as a grant or award, with no entries indicating dispositions, open market sales, or other types of share reductions during the reported period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUNCAN BARBARA GAYLE

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.65	02/26/2026		A		65,000		(1)	02/25/2036	Common Stock	65,000	$0	65,000	D

Explanation of Responses:

1. The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Jeffrey Rona, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.